← Back to All US Stocks

CRLBF Stock Analysis - Cresco Labs Inc. AI Rating

CRLBF OTC Medicinal Chemicals & Botanical Products A1 CIK: 0001832928
Recently Updated • Analysis: Mar 23, 2026 • SEC Data: 2026-03-23
AI Rating
SELL
95% Confidence

📊 CRLBF Key Takeaways

Revenue: N/A
Net Margin: N/A
Free Cash Flow: N/A
Current Ratio: N/A
Debt/Equity: N/A
EPS: $0.00
AI Rating: SELL with 95% confidence

Investment Thesis

Cresco Labs' financial data is completely unavailable in SEC EDGAR, with only 1 metric available and no data freshness information, indicating potential non-compliance, delisting status, or failure to file required reports. The absence of any fundamental metrics (revenue, profitability, assets, cash flow) makes fundamental analysis impossible and presents severe information risk to investors.

CRLBF Strengths

  • -No strengths identified

CRLBF Risks

  • ! No financial data available - unable to assess revenue, profitability, or financial position
  • ! Likely non-filer or delisted status given absence of recent SEC filings with substantive financial information
  • ! Zero insider filings in last 90 days suggests potential company distress or inactive management trading
  • ! Medicinal chemicals sector subject to regulatory uncertainty, particularly cannabis-related companies facing federal legal restrictions
  • ! Insufficient data to evaluate liquidity, solvency, operational efficiency, or growth prospects

Key Metrics to Watch

CRLBF Financial Metrics

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

CRLBF Profitability Ratios

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

CRLBF vs Default Sector

How Cresco Labs Inc. compares to Default sector averages

Net Margin
CRLBF 0.0%
vs
Sector Avg 12.0%
CRLBF Sector
ROE
CRLBF 0.0%
vs
Sector Avg 15.0%
CRLBF Sector
Current Ratio
CRLBF 0.0x
vs
Sector Avg 1.8x
CRLBF Sector
Debt/Equity
CRLBF 0.0x
vs
Sector Avg 0.7x
CRLBF Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

CRLBF Balance Sheet & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

CRLBF Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

CRLBF SEC Filings

Access official SEC EDGAR filings for Cresco Labs Inc. (CIK: 0001832928)

📋 Recent SEC Filings

Date Form Document Action
Feb 16, 2024 SC 13D feb2024_manning13d.htm View →
Feb 16, 2024 SC 13D feb2024_sampson13d.htm View →
Feb 16, 2024 SC 13G formsc13g_bachtellx21624.htm View →
Feb 14, 2024 SC 13G formsc13g_bachtell.htm View →
Feb 14, 2024 SC 13G formsc13g_sergi.htm View →

Frequently Asked Questions about CRLBF

What is the AI rating for CRLBF?

Cresco Labs Inc. (CRLBF) has an AI rating of SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.

What are CRLBF's key strengths?

.

What are the risks of investing in CRLBF?

No financial data available - unable to assess revenue, profitability, or financial position. Likely non-filer or delisted status given absence of recent SEC filings with substantive financial information.

What is CRLBF's revenue and growth?

Cresco Labs Inc. reported revenue of N/A.

Does CRLBF pay dividends?

Cresco Labs Inc. does not currently pay dividends.

Where can I find CRLBF SEC filings?

Official SEC filings for Cresco Labs Inc. (CIK: 0001832928) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is CRLBF's EPS?

Cresco Labs Inc. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 23, 2026 | Data as of: 2026-03-23 | Powered by Claude AI